Cite
Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the UK and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
MLA
Yiu, Z. Z. N., et al. Infliximab Is Associated with an Increased Risk of Serious Infection in Patients with Psoriasis in the UK and Republic of Ireland: Results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Feb. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......2761..50c4559e45eb718290e28385f0776943&authtype=sso&custid=ns315887.
APA
Yiu, Z. Z. N., Ashcroft, D. M., Evans, I., McElhone, K., Lunt, M., Smith, C. H., Walton, S., Murphy, R., Reynolds, N. J., Ormerod, A. D., Griffiths, C. E. M., Warren, R. B., Irshad, S., Wilde, V., Tahir, S., Ali, H., Mason, K., Hussain, S., Granger, E., … Warren, R. (2019). Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the UK and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Chicago
Yiu, Z. Z. N., D. M. Ashcroft, I Evans, K. McElhone, M. Lunt, C. H. Smith, S. Walton, et al. 2019. “Infliximab Is Associated with an Increased Risk of Serious Infection in Patients with Psoriasis in the UK and Republic of Ireland: Results from the British Association of Dermatologists Biologic Interventions Register (BADBIR),” February. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......2761..50c4559e45eb718290e28385f0776943&authtype=sso&custid=ns315887.